Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04174625
Other study ID # DRGS-2014-2015-165-5
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 25, 2020
Est. completion date December 15, 2021

Study information

Verified date February 2022
Source Applied Science Private University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The effect of omega 3 fatty acid on serum 25-hydroxyvitamin D levels.


Description:

No data are available on the effect of omega 3 on serum 25-hydroxyvitamin D levels in Jordanian men and women. This study was designed to investigate whether omega 3 supplementation has a potential effect on the reducing of serum 25-hydroxyvitamin D levels. This randomized, placebo-controlled clinical trial (RCT) was designed to evaluate 300 mg omega-3FA daily for 2 months on serum levels of 25-hydroxyvitamin D levels. This RCT will be conducted on 80 to 90 Jordanian men and women aged 22 to 66 years. Baseline and follow-up levels for 25-hydroxyvitamin D (25OHD), parathyroid hormone (PTH), calcium, phosphate, liver and kidney functions will be assayed.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date December 15, 2021
Est. primary completion date July 17, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 22 Years to 66 Years
Eligibility Inclusion Criteria: Age =18 years old Male and female Jordanian ASU students and employees who live in Amman. Informed written consent from the participant prior to the start of the study. a serum 25(OH)D concentration between 10 and 70 ng/mL. Exclusion Criteria: Any eligiable subject refuses to apply with informed written consent before the start of the study. Men or women previously diagnosed with chronic diseases, including kidney disease or GIT problems. Who are receiving vitamin D3 supplements (3 months before the start of the study) . Pregnants,Breastfeeding females ,Females using hormonal contraceptives

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Dietary Supplement: Omega3-FA
Dietary Supplement: Omega3-FA 300 mg of omega3-FA once daily for 8 weeks

Locations

Country Name City State
Jordan Mahmoud S Abu-Samak Amman

Sponsors (1)

Lead Sponsor Collaborator
Applied Science Private University

Country where clinical trial is conducted

Jordan, 

Outcome

Type Measure Description Time frame Safety issue
Other serum concentration of calcium mg/dl 8 weeks
Other serum concentration of phosphate mg/dl 8 weeks
Other serum ALT U/L 8 weeks
Other Serum urea mg/dL 8 weeks
Primary serum concentrations of 25-hydroxyvitamin D ng/ml 8 weeks
Primary serum concentrations of PTH pg/mL 8 weeks